Cancer Discov. 2021 May;11(5):OF2. doi: 10.1158/2159-8290.CD-NB2021-0309. Epub 2021 Feb 5.
The KRAS inhibitor sotorasib continues to impress in non-small cell lung cancer: In the phase II CodeBreak 100 trial, the agent elicited responses in more than a third of patients and led to a median progression-free survival of almost 7 months. Based on these results, Amgen has filed for the drug's approval with the FDA and the European Medicines Agency.
KRAS抑制剂索托拉西布在非小细胞肺癌治疗中持续展现出色效果：在II期CodeBreak 100试验中，该药物使超过三分之一的患者产生反应，并导致中位无进展生存期接近7个月。基于这些结果，安进公司已向美国食品药品监督管理局和欧洲药品管理局提交了该药物的批准申请。
